Active ingredientZorifertinibCat. No. P-Z028-001CAS 1626387-80-1Family · Pharmaceutical analytical standards
Zorifertinib
An EGFR tyrosine kinase inhibitor approved in China in 2024 for non-small cell lung cancer with EGFR mutations (exon 19 deletions or the L858R mutation) and metastases in the central nervous system. This family brings together the active ingredient.
Did you know?It was designed specifically to cross the blood-brain barrier: the molecule does not bind the efflux transporters MDR1 and BCRP, which would otherwise pump it back out of the brain.
Go to the active ingredient →Active ingredientZorifertinibCat. No. P-Z028-001CAS 1626387-80-1No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.